Compugen (CGEN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CGEN Compugen

Watchlist

2.3400
+0.4800+25.81%

Close May 22 16:00 ET

209.50MMarket Cap-13000P/E (TTM)

Pre-Market

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Compugen Is Maintained at Buy by Truist Securities
Compugen Is Maintained at Buy by Truist Securities
Dow JonesMay 21 08:19 ET
Express News | Truist Securities Maintains Buy on Compugen, Lowers Price Target to $4
BenzingaMay 21 08:08 ET
Compugen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 118.58% Truist Securities $5 → $4 Maintains Buy 03/08/2024 173.22% Truist Securities $4 → $5 Ma
BenzingaMay 21 08:07 ET
Express News | Compugen Ltd : Truist Securities Cuts Target Price to $4 From $5
ReutersMay 21 00:12 ET
Earnings Call Summary | Compugen(CGEN.US) Q1 2024 Earnings Conference
The following is a summary of the Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript:Financial Performance:Compugen reported a cash balance of approximately $101.3 million as of Q1 2024, including
moomoo AIMay 20 18:04 ET · Conference Call
Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating
Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating.
MT NewswiresMay 20 14:08 ET

Comments

Moomoo AI

Mar 8 19:18

The market anticipates a decline in future revenue, possibly explaining the suppressed P/S. This weak revenue outlook could continue to pressure shares, making it hard to maintain current prices. Shareholders accept the low P/S, expecting future revenue may not bring pleasant surprises.

Compugen Ltd. (NASDAQ:CGEN) Held Back By Insufficient Growth Even After Shares Climb 26%

SlowndEasyTrades

Mar 6 02:00

$Compugen(CGEN.US)$ fk entered very early! now no option to hold at lesast 2 week or more !

SlowndEasyTrades

Mar 5 08:23

$Compugen(CGEN.US)$ 👀looks good i n game 🎲

Moomoo AI

Feb 15 20:06

Michelle Mahler's appointment as Chief Medical Officer is a positive step for Compugen, thanks to her vast clinical development experience. Her leadership in the COM503 Phase 1 study and future role in advancing COM701, COM902, and COM503 are anticipated to significantly boost the company's clinical development strategy.